Study: Abnormal ophthalmologic findings in pediatric and adolescent patients

Article

Awareness of visual impairment in clinical practice is suboptimal, and adherence to ophthalmologic evaluation needs to be improved. The prospective cohort study in the Netherlands included 170 children aged 0 to 18 years with a newly diagnosed brain tumor.

Investigators reported identifying abnormal ophthalmologic findings in 78.8% of patients with a brain tumor and advised an ophthalmologic evaluation at the time of diagnosis to detect early vision loss.1

Myrthe Nuijts, MD, of the Department of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands, and colleagues in this multicenter Dutch study, said, “Ophthalmologic evaluation at diagnosis enables early detection of vision loss, decision-making about treatment, and when applicable, the timely use of visual interventions.”

However, they pointed out, awareness of visual impairment in clinical practice is suboptimal, and adherence to ophthalmologic evaluation needs to be improved.

They conducted a prospective cohort study in 4 centers in the Netherlands that included 170 children aged 0 to 18 years with a newly diagnosed brain tumor between May 15, 2019, and August 11, 2021.

The patients underwent a standardized and comprehensive ophthalmologic examination, including orthoptic evaluation, visual acuity (VA) and visual field evaluations, and ophthalmoscopy within 4 weeks after the brain tumor was diagnosed.

The main outcome measures were the prevalence and types of visual symptoms and abnormal ophthalmologic findings at the time of tumor diagnosis.

Results of ophthalmologic analysis

Of the study patients, 96 were boys (median age, 8.3 years; range, 0.2-17.8 years).

The tumor locations were infratentorial in 82 (48.2%) patients; supratentorial midline in 53 (31.2%); and cerebral hemispheric in 35 (20.6%).

Orthoptic evaluations were conducted in 161 patients (94.7%) underwent orthoptic evaluation (preoperatively in 67, 41.6%; postoperatively in 94, 58.4%).

The VA was tested in 152 (89.4%) patients (preoperatively in 63, 41.4%; postoperatively in 89, 58.6%).

Visual fields were measured in 121 (71.2%) patients (preoperatively in 49, 40.4%; postoperatively in 72 59.6%).

Ophthalmoscopy was performed in 164 (96.5%) patients, preoperatively in 82, 50.0%; postoperatively in 82, 50.0%).

The analysis showed that 101 youths (59.4%) had visual symptoms at tumor diagnosis. Abnormal ophthalmologic findings were identified in 134 patients (78.8%) during the eye examinations.

The most common abnormalities were papilledema in 86 of 164 patients (52.4%) who underwent ophthalmoscopy, gaze deficits in 54 of 161 (33.5%) who underwent orthoptic evaluation, visual field defects in 32 of 114 (28.1%) with reliable visual field examination, nystagmus in 40 (24.8%) and strabismus in 32 (19.9%) of 161 who underwent orthoptic evaluation, and decreased VA in 13 of 152 (8.6%) with reliable VA testing. Forty-five of 69 patients (65.2%) who did not have visual symptoms at the time of tumor diagnosis had ophthalmologic abnormalities on examination, the investigators reported.

“The results suggest that there is a high prevalence of abnormal ophthalmologic findings in youths at brain tumor diagnosis regardless of the presence of visual symptoms. These findings support the need for standardized ophthalmologic examination and the awareness of ophthalmologists and referring oncologists, neurologists, and neurosurgeons for ophthalmologic abnormalities in this patient group,” Dr. Nuijts and colleagues concluded.

Reference
1. Nuijts MA, Stegman I, van Seeters T, et al. Ophthalmological findings in youths with a newly diagnosed brain tumor. JAMA Ophthalmol. Published online September 15, 2022. doi:10.1001/jamaophthalmol.2022.3628

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
At CIME 2025, Selina McGee, OD, FAAO, says some patients underestimate oculoplastic care. She stands in front of a sign that says Controversies in Modern Eye Care 2025.
Rhue and Canto-Sims talk the value of contact lens patients, financial insights, and key benefits of implementing a contact lens management system.
© 2025 MJH Life Sciences

All rights reserved.